Mark Mullen, MD

Dr Mullen is a fourth-year psychiatry resident at Creighton University.

Articles

Zuranolone for the Treatment of Adults With Major Depressive Disorder

Joshua Robak, MD;Lior Hilsenrath, MD;Abigail Jaeger, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

July 12th 2024

This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

Longitudinal Study Looks at Risk of Cardiovascular Disease With Long-Term ADHD Medication Use

Masha Impallaria, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

May 25th 2024

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.

Treatment-Resistant Geriatric Depression: Augmenting or Switching an Antidepressant

Lalangi Marasinghe, MD;Anvesh Jalasutram, MD;Phil Ryan, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

April 17th 2024

Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease

Meagan Kubista, MD;Grethel Perez Meek, DO;Kyle Sramek, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

February 20th 2024

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.